Sareum Holdings plc

AIM:SAR Voorraadrapport

Marktkapitalisatie: UK£31.8m

Sareum Holdings Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Sareum Holdings's earnings have been declining at an average annual rate of -29%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 20.3% per year.

Belangrijke informatie

-29.0%

Groei van de winst

-24.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie14.1%
Inkomstengroei-20.3%
Rendement op eigen vermogen-161.8%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Apr 27
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Aug 06
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Apr 22
We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth

Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

Jan 06
Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

Aug 31
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate

We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

May 07
We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely

What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Dec 23
What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?

Opbrengsten en kosten

Hoe Sareum Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

AIM:SAR Opbrengsten, kosten en inkomsten (GBP Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-350
31 Mar 240-450
31 Dec 230-450
30 Sep 230-440
30 Jun 230-340
31 Mar 230-340
31 Dec 220-330
30 Sep 220-230
30 Jun 220-230
31 Mar 220-220
31 Dec 210-220
30 Sep 210-220
30 Jun 210-120
31 Mar 210-110
31 Dec 200-110
30 Sep 200-110
30 Jun 200-110
31 Mar 200-110
31 Dec 190-110
30 Sep 190-120
30 Jun 190-120
31 Mar 190-120
31 Dec 180-220
30 Sep 180-120
30 Jun 180-120
31 Mar 180-120
31 Dec 170-120
30 Sep 170010
30 Jun 170010
31 Mar 170010
31 Dec 160010
30 Sep 160-110
30 Jun 160-110
31 Mar 160-110
31 Dec 150-110
30 Sep 150-110
30 Jun 150-110
31 Mar 150-110
31 Dec 140-110
30 Sep 140-110
30 Jun 140-110
31 Mar 140-110

Kwaliteitswinsten: SAR is currently unprofitable.

Groeiende winstmarge: SAR is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: SAR is unprofitable, and losses have increased over the past 5 years at a rate of 29% per year.

Versnelling van de groei: Unable to compare SAR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: SAR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


Rendement op eigen vermogen

Hoge ROE: SAR has a negative Return on Equity (-161.78%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden